CompanyBMY CELG-RINYSEPrinceton, NJ

Bristol Myers Squibb

Bristol Myers Squibb discovers, develops, and delivers medicines across oncology, immunology, cardiovascular disease, and cell therapy.

SEC EDGAR ClinicalTrials.gov bms.com

20-FSep 30Latest SEC filing

Sep 30Latest story

September 2026

Mirati's SAPPHIRE trial in NSCLC terminated, results posted on ClinicalTrials.gov

Sep 30Trial updateBristol Myers Squibb nivolumab

BMS registers Phase 1 CAR T cell trial in kidney cancer; adds mavacamten real-world study

Sep 30Weekly roundup, 2 itemsBristol Myers Squibb mavacamtenUpdated

BMS trials update: CheckMate-67T posts results; two studies added for irAE care and lung screening

Sep 25Weekly roundup, 4 itemsBristol Myers Squibb clarithromycin

Incyte posts terminated Phase 1 KRASG12C combo results; registers new INCB161734 mass balance study

Sep 11Weekly roundup, 2 itemsadagrasib Bristol Myers Squibb

BMS logs three FDA label approvals and posts results for melanoma combo trial

Sep 2Weekly roundup, 5 itemsadagrasib Bristol Myers Squibb

August 2026

BMS registers new deucravacitinib continuation study; prior week's trial results still stand

Aug 27Weekly roundup, 5 itemsBristol Myers Squibb deucravacitinib

BMS registers Phase 2 depression trial for BMS-986511; adds Alzheimer's PK study for BMS-986446

Aug 21Weekly roundup, 6 itemsBristol Myers Squibb entecavir

FDA approves Bristol Myers Squibb's Zenbexus, a new molecular entity

Aug 13Regulatory decisionBristol Myers Squibb iberdomide

BMS posts JAKARTA Phase 3 results, updates Opdivo label, registers golcadomide renal study

Aug 13Weekly roundup, 4 itemsBristol Myers Squibb golcadomide

Bristol-Myers Squibb registers observational study of first-line Reblozyl in lower-risk MDS

Aug 7Trial updateBristol Myers Squibb luspatercept

Arcus Biosciences advances casdatifan combinations, reports $775M cash at midyear 2026

Aug 5Quarterly updateArcus Biosciences, Inc.AstraZeneca

July 2026

Results post for old USC gastric cancer trial; Bristol Myers Squibb opens new Zeposia PML study

Jul 30Weekly roundup, 3 itemsBristol Myers Squibb iberdomide

Bristol Myers Squibb raises 2026 guidance, cites pipeline progress across four programs

Jul 30Quarterly updateBristol Myers Squibb luspatercept

BMS week: two label updates, new luspatercept CKD trial, pulmonary fibrosis study registered

Jul 24Weekly roundup, 6 itemsadagrasib Bristol Myers Squibb

BMS trials post results across lung cancer, sarcoma, myelofibrosis; new stroke study opens

Jul 17Weekly roundup, 5 itemsBristol Myers Squibb lisocabtagene maraleucel

Karuna/BMS opens Phase 3 KarXT relapse prevention trial in schizophrenia

Jul 7Weekly roundup, 2 itemsBristol Myers Squibb pomalidomide

BMS posts PRIME-HCC results; adds SOTYKTU label update, Phase 3 lung trial

Jul 2Weekly roundup, 7 itemsBristol Myers Squibb cisplatin

Pipeline by stage

Phase 3 primary completions, next 6 months

Oct 2026xanomeline and trospium chloridepsychosis associated with alzheimer's disease · NCT05511363

Nov 2026xanomeline and trospium chloridebipolar-i disorder with mania or mania with mixed features · NCT06951698

Nov 2026xanomeline and trospium chloridebipolar disorder type i with mania or mania with mixed features · NCT06951711

Nov 2026xanomeline and trospium chloridealzheimer disease · NCT06585787

Nov 2026xanomeline and trospium chloridehealthy volunteers · NCT07681076

Dec 2026xanomeline and trospium chloridepsychosis associated with alzheimer's disease · NCT06126224

Details

Headquarters: Princeton, NJ
Incorporated: Delaware
Industry: Pharmaceutical Preparations
Also known as: BMY, BRISTOL, Bristol-Myers, BRISTOL MYERS SQUIBB CO, and 12 more
Bristol-Myers Squibb Services Unlimited Company, CELG-RI, Celgene, E.R. Squibb & Sons, Juno Therapeutics, Juno Therapeutics, Inc., a Bristol-Myers Squibb Company, Karuna Therapeutics, Karuna Therapeutics, Inc., a Bristol Myers Squibb company, Mirati Therapeutics, MyoKardia, RayzeBio, Turning Point Therapeutics

Relationships

Licensor to danicamtiv

How the company describes itself

Bristol Myers Squibb discovers, develops, and delivers medicines across oncology, immunology, cardiovascular disease, and cell therapy. The company's pipeline includes small molecules, biologics, and cell therapies targeting cancer, autoimmune conditions, and heart disease. source